Ed Arce
Stock Analyst at WestPark Capital
(3.78)
# 674
Out of 5,129 analysts
376
Total ratings
46.2%
Success rate
9.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $24 → $28 | $14.16 | +97.74% | 13 | Sep 30, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $30.40 | -1.30% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $132 | $1.66 | +7,851.81% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $6.07 | +1,136.60% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $7.24 | +728.73% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $1.46 | +413.70% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $6.20 | +109.85% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $2.73 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.86 | +597.67% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $7.10 | +885.90% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $26.50 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $1.90 | +12,531.58% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.12 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $5.10 | +527.45% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $101.92 | -29.36% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $480.76 | -15.76% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $7.16 | -23.13% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $23.41 | +305.81% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.87 | +29.20% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $34.90 | +37.54% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $38.24 | -80.39% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.29 | +1,612.33% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $14.30 | -9.09% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $41.97 | -40.43% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.61 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.85 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $31.25 | -77.60% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $45.84 | -54.19% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.33 | - | 2 | Feb 15, 2017 |
Enanta Pharmaceuticals
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $14.16
Upside: +97.74%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $30.40
Upside: -1.30%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $132
Current: $1.66
Upside: +7,851.81%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $6.07
Upside: +1,136.60%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $7.24
Upside: +728.73%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $1.46
Upside: +413.70%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $6.20
Upside: +109.85%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $2.73
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.86
Upside: +597.67%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $7.10
Upside: +885.90%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $26.50
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $1.90
Upside: +12,531.58%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.12
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $5.10
Upside: +527.45%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $101.92
Upside: -29.36%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $480.76
Upside: -15.76%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $7.16
Upside: -23.13%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $23.41
Upside: +305.81%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $3.87
Upside: +29.20%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $34.90
Upside: +37.54%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $38.24
Upside: -80.39%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.29
Upside: +1,612.33%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $14.30
Upside: -9.09%
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $41.97
Upside: -40.43%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.61
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $14.85
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $31.25
Upside: -77.60%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $45.84
Upside: -54.19%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $4.33
Upside: -